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Objective/background: Sickle-cell anemia (SCA) is a genetic blood disease characterized by
chronic inflammation and a heterogeneous clinical picture. Serum tumor necrosis factor
(TNF-alpha) and interleukin 10 (IL-10) levels are associated with the clinical course of SCA. This
study aimed to evaluate the association between the frequency of the polymorphisms TNF-
alpha-308 G? A, IL-10-1082 G? A, IL-10-819 C? T, and IL-10-592 A? C; serum TNF-alpha;
and IL-10 levels, and the incidence of clinical events in SCA patients.
Methods: Polymerase chain reaction–restriction fragment length polymorphism and enzyme-
linked immunosorbent assay were performed on 25 adults with SCA at the steady state; their
data were compared with those for 26 healthy individuals.sco Pedro,
Clinical events and their relation to the TNF-alpha and IL-10 genotypes 15Results: The most frequent genotype of the TNF-alpha polymorphism was GG (low producer),
and the most frequent genotype of the IL-10 polymorphisms was ‘‘low producer” (ACC ACC, ACC
ATA, ATA ATA). The TNF-alpha levels were significantly higher in SCA in patients with acute
chest syndrome (ACS). The IL-10 levels were reduced in polytransfusion and in patients with ACS.
Conclusion: The patients presented prevalence of TNF-alpha and IL-10 low-profile producer.
The cytokine serum levels presented an association with the presence of polytransfusion and
ACS in SCA patients.
 2015 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Sickle-cell anemia (SCA) results from a point mutation, in
which an adenine nucleobase in the sixth codon of the b-
globin gene is replaced by a thymine (GAG? GTG). The
molecular translation replaces glutamic acid with valine,
thereby producing an abnormal form of hemoglobin called
hemoglobin S [1]. Although the molecular lesion is limited
to a single nucleotide, the SCA gene is pleiotropic and leads
to multiple phenotypic expressions. SCA patients may pre-
sent with various complications, such as recurrent episodes
of vaso-occlusion, acute chest syndrome (ACS), stroke,
infections, and priapism. These complications vary consid-
erably among patients and over time [2–4].
The repeated polymerization of hemoglobin S can cause
definitive damage to the structure of red blood cells, pro-
ducing mainly intravascular hemolysis and vaso-occlusion,
and triggering a cyclical cascade of reactions that culmi-
nates with the generation of reactive oxygen species and
increased oxidative stress, reduced bioavailability of nitric
oxide, endothelial injury, hypercoagulability, increased
expression of adhesion molecules in blood and endothelial
cells, ischemia/reperfusion injury, and chronic inflamma-
tion. Alone or in combination, these reactions are associated
with inflammatory responses in various organs and can pro-
duce an array of other secondary pathological conditions [5].
For reasons not yet fully understood, the clinical outcome
of SCA is highly variable. Several factors have been identified
as modulators of clinical severity in SCA, including fetal
hemoglobin (HbF) levels, association with a-thalassemia,
b-globin haplotypes, and the presence of single-nucleotide
polymorphisms (SNPs) [6–8]. SNPs are sites in which the
genomic DNA sequence of a percentage of individuals in
the population differs by a single base. It is the most com-
mon type of variation in the human genome [9].
Some authors have hypothesized that the phenotype of
SCA patients is modulated by polymorphisms in genes
involved in inflammation, cell interaction (vascular cell
adhesion molecule 1, complement receptor 1, P-selectin,
and alpha V integrin), modulation of oxidant injury, and
nitric-oxide biology (nitric oxide synthase 2, nitric oxide
synthase 3, and arginase, type II) [10–12].
The polymorphism tumor necrosis factor (TNF-alpha)-308
G? A has been shown to be associated with an increased
risk of stroke in patients with SCA [13]. The polymorphism
in the interleukin 10 (IL-10) gene is expressed in three geno-
types: AA, AG, and GG, associated with low, intermediate,
and high IL-10 production, respectively.Synthesized mainly by activated mononuclear phago-
cytes, TNF-alpha is the main mediator of acute inflamma-
tory response. It acts by recruiting neutrophils and
monocytes to the site of inflammation through a variety of
mechanisms [14]. IL-10 acts directly on cluster of differen-
tiation 4+ T cells inhibiting the proliferation and production
of IL-2, interferon gamma, IL-4, IL-5, and TNF.
Importantly, cytokine-gene polymorphisms and serum
concentrations of cytokines have been correlated with clin-
ical heterogeneity in SCA. In addition, polymorphisms may
act as modulating factors by inducing changes that can
potentially interfere with important pathways involved in
the pathophysiology of the disease. The phenotypes typi-
cally observed in SCA have been associated with polymor-
phisms in genes encoding cytokines. Thus, much attention
has been given to the development of markers susceptible
to specific SCA-related phenotypes and laboratory abnor-
malities with the purpose of preventing or minimizing clini-
cal symptoms through early intervention. The objective of
the present study was to evaluate the association between
the frequency of the polymorphisms TNF-alpha-308 G? A,
IL-10-1082 G? A, IL-10-819 C? T, and IL-10-592 A? C;
serum TNF-alpha; and IL-10 levels, and the incidence of
clinical events in a sample of Brazilian SCA patients.
Materials and methods
Participants
This analytical study was based on a cross-sectional sample
of 25 adults diagnosed with SCA attending the hematology
outpatient service of the Walter Cantı´dio University Hospi-
tal in Fortaleza, Brazil, in 2013 and 2014. All patients were
at the steady state in accordance with the criteria proposed
by Ballas (2012) [15]: absence of painful episodes and/or
intercurrent illnesses, such as infections and inflammation in
the 4 weeks preceding the study; no hospital admissions in
the 3 days preceding the study; and no blood transfusions
in the 4 months preceding the study. Patients with infec-
tious diseases, hemoglobin profiles incompatible with SCA,
history of blood transfusion within the preceding 4 months,
and/or inflammatory episodes during the study were
excluded. Clinical data, complete blood count, and HbF val-
ues were collected from the patients’ medical records.
Demographic data were obtained through interviews with
the patients. The study protocol was approved by the Wal-
ter Cantı´dio University Hospital Research Ethics Committee.
All patients and controls gave their informed written
16 J.E.A. Cavalcante et al.consent, and all study procedures followed the guidelines
set forth in Resolution 466/12 of the National Health Coun-
cil, which regulates research involving human participants.
The control group consisted of 26 healthy individuals
(HbAA), adults, volunteers, and both sexes, with aleatory
selection and enrolled in the Pharmacy School of the Fed-
eral University of Ceara´. They had normal hemoglobin pro-
files, and no recent history of anemia, inflammatory
conditions, or hematological disease.
Serum levels of TNF-alpha and IL-10
The serum TNF-alpha and IL-10 levels were measured by
enzyme-linked immunosorbent assay (BD Biosciences,
Pharmingen, California, USA), following the manufacturer’s
instructions.
Typing of SNPs
Genomic DNA was extracted from leukocytes and stored at
80C until the moment of typing. The TNF-alpha-308
G? A, IL-10-1082 G? A, IL-10-819 C? T, and IL-10-592
A? C polymorphisms were evaluated by polymerase chain
reaction and restriction fragment length polymorphism, as
described elsewhere [16,17]. The polymorphisms were strat-
ified according to the TNF-alpha profile: AA (high producer),
GA (intermediate producer), and GG (low producer), and IL-
10 profile: GCC GCC (high producer), GCC ATA GCC ACC
(intermediate producer), and ACC ACC ACC ATA ATA ATA
(low producer). The association between the genotype and
the cytokine profile (high/intermediate/low producer) was
determined using the reference values specified by the man-
ufacturer of the typing kit One Lambda (Canoga Park, CA,
USA) and data published in the literature [17].
Statistical analysis
The associations between polymorphisms and clinical events
were analyzed with the two-tailed Fisher’s exact test, while
the Kruskal–Wallis test, the unpaired t test, and the Mann–
Whitney test were used to assess the relationship between
the genotypes of the polymorphisms and the respective
serum cytokine levels, and to compare patients and con-
trols. The p values were calculated for each comparison.
The level of statistical significance was set at 5% (p < .05),
with a 95% confidence interval.
Results
The hematologic details of the SCA patients can be observed
in Table 1.
The study included 25 SCA patients (11 women and 14
men) aged 35.72 years on the average (range: 19–63 years)
and 26 healthy controls (19 women and 7 men) with an aver-
age age of 32.2 years (18–59 years). The most frequently
observed clinical complication was pain crisis (75%), fol-
lowed by polytransfusion and hospitalization (both 46.4%),
leg ulcers (42.9%), gallstones (32.1%), and ACS and avascular
necrosis of the femoral head (both 14.3%) (Table 1).The average TNF-alpha levels were significantly higher in
SCA patients (27.01 pg/mL) than in controls (4.34 pg/mL)
(p = .0089) (Figure 1).
The IL-10 serum levels were not significantly different
between the SCA patients (10.93 pg/mL) and the control
group (9.98 pg/mL) (p = .5088) (Figure 2).
The most frequent genotype of patients with the
TNF-alpha-308 G? A polymorphism was GG (low producer/
n = 20; 80%), followed by GA (intermediate producer/n = 5;
20%). None of the patients were AA (high producer/
n = 0; 0%).
The most frequent genotype of patients with the IL-10-
1082 G? A, IL-10-819 C? T, and IL-10-592 A? C gene
polymorphisms was ACC ACC, ACC ATA, ATA ATA (low pro-
ducer/n = 13; 52%), followed by ATA GCC, GCC ACC (inter-
mediate producer/n = 10; 40%) and GCC GCC (high
producer/n = 2; 8%) (Table 2).
The patients showed no significant difference in serum
levels of cytokines when compared in relation to the IL-10
and TNF-alpha producer cytokine profile.
The SCA patients with ACS showed a significant increase
in TNF-alpha serum levels (p = .0417) (Figure 3), and IL-10
serum levels presented reduced significantly in polytrans-
fused patients (p = .0485) (Figure 4). The patients with IL-
10 low-profile producer showed a significant association
with the presence of ACS (p = .0463) (Figure 5).
Discussion
Our sample of patients presented a hematological profile
typical of SCA: normochromic and normocytic anemia,
leukocytosis, and increased HbF levels. The finding of mod-
erate anemia, mild leukocytosis, and high HbF levels even in
steady-state patients is supported by the literature. An
excellent marker of severity of SCA, increased HbF levels
are associated with a reduction in episodes of vaso-
occlusion, transfusions, and hospitalizations [18,19]. The
high HbF levels observed in this study may also be attributed
to the use of hydroxyurea, which has been documented to
increase the HbF concentrations in SCA patients.
In this study, the most frequent clinical complication was
pain crisis, followed by hospitalization, blood transfusion,
and recurrent infection. This matches the findings of Boas,
Cerqueira, Zanette, Reis, and Gonc¸alves (2010) [20] for
adult patients with active SCA treated at a referral center
in Salvador (Bahia, Brazil).
Produced by macrophages and T lymphocytes, TNF-alpha
is known for its pro-inflammatory activities, including the
activation of endothelial cells, stimulation of inflammation,
induction of the coagulation cascade, synthesis of acute-
phase proteins, activation of neutrophils, and stimulation
of neutrophil adhesion. Thus, increased serum TNF levels
in SCA patients indicate a persisting inflammatory process.
In the present study, the TNF-alpha levels were significantly
higher among patients than controls. This finding agrees
with other studies that have shown this cytokine to be ele-
vated in children and adults with SCA both in the steady
state and during crisis [21–23]. The increase in TNF-alpha
levels is due to chronic inflammatory processes, even in
steady-state SCA [24,25].
Table 1 Hematologic details of Sickle-Cell-Anemia
patients (n = 25).
Age (y) 37.28 (range: 19–63)
Gender
Male 14 (50%)
Female 11 (50%)
Hb (g/dL) 8.147 ± 1.129
Hematocrit (%) 25.35 ± 3.753
MCV (fL) 92.20 ± 12.84
MCHC (%) 33.12 ± 1.919
Leukocytes (/mm3) 11,091 ± 4,403
Platelets (/mm3) 432,854 ± 112,640
HbF (%) 7.475 ± 4.175
Note. Data values are expressed as mean ± standard error of the
mean (SEM). Hb = hemoglobin; HbF = fetal hemoglobin;
MCHC = mean corpuscular hemoglobin concentration;
MCV = Mean Corpuscular Volume.
Figure 1 Serum tumor necrosis factor-alpha levels of 25
sickle-cell-anemia adult patients in steady state and 26 healthy
controls. SCA = sickle-cell anemia; TNF = tumor necrosis factor.
Figure 2 Serum IL-10 levels of 28 SCA adult patients in steady
state and 26 healthy controls. IL = interleukin; SCA = sickle-cell
anemia.
Table 2 Tumor Necrosis Factor-Alpha and Interleukin-10
Genotype Frequency in 25 Sickle-Cell-Anemia Patients in
Steady State.
TNF-alpha genotypes Frequency Profile
GA 5 (20%) Intermediate producer
GG 20 (80%) Low producer
AA 0 (0%) High producer
IL-10 genotypes Frequency Profile
ACC ACC 1 (4%) Low producer
ACC ATA 7 (28%) Low producer
ATA ATA 5 (20%) Low producer
GCC ATA 5 (20%) Intermediate producer
GCC ACC 5 (20%) Intermediate producer
GCC GCC 2 (8%) High producer
Note. IL = interleukin; TNF = tumor necrosis factor.
Figure 3 Serum TNF-alpha levels in patients with and without
acute chest syndrome (Mann–Whitney test). TNF = tumor
necrosis factor.
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Figure 4 Serum IL-10 levels in patients with and without
polytransfusion (Mann–Whitney test). IL-10 = interleukin-10.
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inflammatory cytokine that contributes to regulating the
production of pro-inflammatory cytokines. In this study,
the patients and controls did not differ significantly withregard to IL-10 levels. Likewise, Graido-Gonzalez et al.
(1998) [26] found the IL-10 levels in adults with SCA to
increase during crisis, but not in the steady state.
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Figure 5 Serum IL-10 levels of 25 SCA adult patients in steady
state according to the genotype of polymorphism in the IL-10
gene (Fisher’s Fisher’s exact test). IL = interleukin; SCA, sickle-
cell anemia.
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alpha-308 G? A polymorphism was GG (80%), followed by
GA (20%) and AA (0%). From the study by Cajado et al.
(2011) [22] based on a sample of SCA patients from Brazil
northeast, Bahia, the frequency follows the same profile:
80.2%, 18.2%, and 1.6%. In SCA patients from the state of
Sa˜o Paulo, Brazil, the frequency was 83.7% for GG and
16.3% for GA [27]. According to Hoppe et al. (2007) [13],
in a sample of African–American children classified as HbSS,
GG was observed with a frequency of 75%.
In our study, polymorphisms were typed in the IL-10 gene
regions -1082 G? A, -819 C? T, and -592 A? C. The geno-
type ACC/ATA was the most frequent among the patients
(25.0%).
As expected, in the patient group, the serum TNF-alpha
levels were higher for GA (intermediate producer) than
for GG (low producer), although the difference was not
statistically significant. This indicates that the GG genotype
of the TNF-alpha-308 G? A polymorphism in the population
studied is associated with a good prognosis with regard to low
serum TNF-alpha production. However, when the genotypes
were correlated with serum concentrations, an increase in
TNF-alpha levels was observed, supporting the hypothesis
of a multifactorial etiology. In addition, Cajado et al.
(2011) [22] found an association between the A allele of
the TNF-alpha-308 G? A polymorphism and the increased
serum TNF-alpha levels in adults with SCA in the steady state.
Clinical events, such as leg ulcers, ACS, femoral necrosis,
and recurrent infection, were more frequent in patients with
increased serum levels of TNF-alpha, but the difference was
only significant for ACS. Defined as the appearance of new
pulmonary infiltrate along with respiratory symptoms or
chest pain, ACS is the most common cause of death and
the second most common cause of hospitalization in adult
SCA patients. All these events are associated with chronic
inflammation, and TNF-alpha is a pro-inflammatory cytokine
[27]. Serum IL-10 levels were reduced in patients with ACS
and blood transfusion. Polytransfusion in response to severe
anemia often leads to iron overload. Interestingly, another
study based on the same patients showed serum IL-10 levels
to be lower in participants with than without iron overload
secondary to polytransfusion [28]. The main effect of IL-10is to inhibit the synthesis of other cytokines, such as inter-
feron alpha, IL-2, IL-12, and TNF-b. Sarray, Mahdi, Saleh,
and Almaoui (2014) [29] demonstrated that decreased serum
IL-10 levels is a predictor of vaso-occlusive crisis in SCA.
Little research has been published on the association
between cytokine-gene polymorphisms, serum cytokine con-
centrations, and clinical events in SCA. Much remains to be
clarified regarding the dynamics of TNF-alpha and IL-10 in
SCA, and their use as markers of vaso-occlusive crisis.
Conclusions
Our results showed that SCA patients in the Ceara´, Brazil
showed an increase in TNF-alpha production and a predom-
inance of low-profile producer of the cytokines IL-10 and
TNF-alpha. IL-10 low levels were associated with the pres-
ence of multiple transfusions. Patients with ACS were asso-
ciated with increased TNF-alpha production and low IL-10.
Additional studies are needed to clarify the mechanisms
involved in infectious processes in such patients in order
to establish the prognostic value of genetic polymorphisms
in the development of SCA-related clinical complications.
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